Intrinsic value of Chimerix - CMRX

Previous Close

$3.17

  Intrinsic Value

$1.16

stock screener

  Rating & Target

str. sell

-63%

Previous close

$3.17

 
Intrinsic value

$1.16

 
Up/down potential

-63%

 
Rating

str. sell

We calculate the intrinsic value of CMRX stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.2

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  7
  11
  17
  24
  34
  47
  63
  82
  106
  134
  166
  203
  245
  292
  343
  399
  459
  525
  594
  668
  746
  828
  914
  1,005
  1,099
  1,197
  1,300
  1,406
  1,517
  1,632
Variable operating expenses, $m
  31
  47
  71
  102
  145
  199
  267
  350
  451
  569
  707
  864
  1,042
  1,239
  1,457
  1,695
  1,953
  2,229
  2,525
  2,839
  3,170
  3,520
  3,886
  4,270
  4,671
  5,089
  5,524
  5,977
  6,448
  6,938
Fixed operating expenses, $m
  62
  64
  65
  67
  68
  70
  71
  73
  74
  76
  77
  79
  81
  83
  85
  86
  88
  90
  92
  94
  96
  98
  101
  103
  105
  107
  110
  112
  115
  117
Total operating expenses, $m
  93
  111
  136
  169
  213
  269
  338
  423
  525
  645
  784
  943
  1,123
  1,322
  1,542
  1,781
  2,041
  2,319
  2,617
  2,933
  3,266
  3,618
  3,987
  4,373
  4,776
  5,196
  5,634
  6,089
  6,563
  7,055
Operating income, $m
  -86
  -100
  -119
  -145
  -179
  -221
  -275
  -340
  -419
  -511
  -618
  -740
  -877
  -1,030
  -1,199
  -1,383
  -1,582
  -1,795
  -2,023
  -2,265
  -2,521
  -2,790
  -3,073
  -3,368
  -3,677
  -3,999
  -4,334
  -4,683
  -5,046
  -5,422
EBITDA, $m
  -85
  -99
  -117
  -142
  -175
  -216
  -268
  -331
  -406
  -495
  -598
  -716
  -848
  -996
  -1,158
  -1,335
  -1,527
  -1,733
  -1,953
  -2,186
  -2,432
  -2,692
  -2,964
  -3,249
  -3,547
  -3,857
  -4,180
  -4,516
  -4,866
  -5,229
Interest expense (income), $m
  0
  0
  1
  1
  2
  4
  5
  8
  11
  14
  19
  24
  30
  36
  44
  52
  62
  72
  83
  95
  107
  121
  135
  150
  165
  182
  199
  217
  236
  255
  275
Earnings before tax, $m
  -86
  -100
  -120
  -147
  -182
  -227
  -283
  -351
  -433
  -530
  -642
  -770
  -914
  -1,074
  -1,251
  -1,444
  -1,653
  -1,878
  -2,118
  -2,372
  -2,642
  -2,925
  -3,222
  -3,534
  -3,859
  -4,198
  -4,551
  -4,919
  -5,301
  -5,697
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -86
  -100
  -120
  -147
  -182
  -227
  -283
  -351
  -433
  -530
  -642
  -770
  -914
  -1,074
  -1,251
  -1,444
  -1,653
  -1,878
  -2,118
  -2,372
  -2,642
  -2,925
  -3,222
  -3,534
  -3,859
  -4,198
  -4,551
  -4,919
  -5,301
  -5,697

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  175
  271
  405
  588
  830
  1,140
  1,531
  2,010
  2,586
  3,267
  4,057
  4,959
  5,978
  7,112
  8,363
  9,728
  11,206
  12,794
  14,490
  16,291
  18,195
  20,200
  22,304
  24,506
  26,807
  29,205
  31,703
  34,303
  37,005
  39,814
Adjusted assets (=assets-cash), $m
  175
  271
  405
  588
  830
  1,140
  1,531
  2,010
  2,586
  3,267
  4,057
  4,959
  5,978
  7,112
  8,363
  9,728
  11,206
  12,794
  14,490
  16,291
  18,195
  20,200
  22,304
  24,506
  26,807
  29,205
  31,703
  34,303
  37,005
  39,814
Revenue / Adjusted assets
  0.040
  0.041
  0.042
  0.041
  0.041
  0.041
  0.041
  0.041
  0.041
  0.041
  0.041
  0.041
  0.041
  0.041
  0.041
  0.041
  0.041
  0.041
  0.041
  0.041
  0.041
  0.041
  0.041
  0.041
  0.041
  0.041
  0.041
  0.041
  0.041
  0.041
Average production assets, $m
  4
  7
  10
  14
  20
  28
  37
  49
  63
  79
  98
  120
  145
  173
  203
  236
  272
  311
  352
  395
  442
  490
  541
  595
  651
  709
  770
  833
  898
  966
Working capital, $m
  -15
  -23
  -34
  -49
  -70
  -96
  -128
  -169
  -217
  -274
  -340
  -416
  -501
  -597
  -702
  -816
  -940
  -1,073
  -1,216
  -1,367
  -1,526
  -1,694
  -1,871
  -2,056
  -2,249
  -2,450
  -2,659
  -2,878
  -3,104
  -3,340
Total debt, $m
  11
  24
  43
  68
  101
  144
  198
  264
  344
  438
  547
  671
  812
  968
  1,141
  1,329
  1,533
  1,752
  1,986
  2,235
  2,498
  2,774
  3,065
  3,369
  3,686
  4,017
  4,362
  4,721
  5,094
  5,481
Total liabilities, $m
  24
  37
  56
  81
  114
  157
  211
  277
  357
  451
  560
  684
  825
  982
  1,154
  1,342
  1,546
  1,766
  2,000
  2,248
  2,511
  2,788
  3,078
  3,382
  3,699
  4,030
  4,375
  4,734
  5,107
  5,494
Total equity, $m
  151
  234
  349
  507
  715
  983
  1,319
  1,733
  2,229
  2,816
  3,497
  4,275
  5,153
  6,131
  7,209
  8,386
  9,660
  11,029
  12,490
  14,043
  15,684
  17,412
  19,226
  21,124
  23,107
  25,175
  27,328
  29,569
  31,898
  34,320
Total liabilities and equity, $m
  175
  271
  405
  588
  829
  1,140
  1,530
  2,010
  2,586
  3,267
  4,057
  4,959
  5,978
  7,113
  8,363
  9,728
  11,206
  12,795
  14,490
  16,291
  18,195
  20,200
  22,304
  24,506
  26,806
  29,205
  31,703
  34,303
  37,005
  39,814
Debt-to-equity ratio
  0.070
  0.100
  0.120
  0.130
  0.140
  0.150
  0.150
  0.150
  0.150
  0.160
  0.160
  0.160
  0.160
  0.160
  0.160
  0.160
  0.160
  0.160
  0.160
  0.160
  0.160
  0.160
  0.160
  0.160
  0.160
  0.160
  0.160
  0.160
  0.160
  0.160
Adjusted equity ratio
  0.862
  0.862
  0.862
  0.862
  0.862
  0.862
  0.862
  0.862
  0.862
  0.862
  0.862
  0.862
  0.862
  0.862
  0.862
  0.862
  0.862
  0.862
  0.862
  0.862
  0.862
  0.862
  0.862
  0.862
  0.862
  0.862
  0.862
  0.862
  0.862
  0.862

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -86
  -100
  -120
  -147
  -182
  -227
  -283
  -351
  -433
  -530
  -642
  -770
  -914
  -1,074
  -1,251
  -1,444
  -1,653
  -1,878
  -2,118
  -2,372
  -2,642
  -2,925
  -3,222
  -3,534
  -3,859
  -4,198
  -4,551
  -4,919
  -5,301
  -5,697
Depreciation, amort., depletion, $m
  1
  1
  2
  3
  4
  6
  7
  10
  13
  16
  20
  24
  29
  35
  41
  47
  54
  62
  70
  79
  88
  98
  108
  119
  130
  142
  154
  167
  180
  193
Funds from operations, $m
  -85
  -99
  -118
  -144
  -178
  -221
  -275
  -341
  -421
  -514
  -622
  -745
  -885
  -1,040
  -1,211
  -1,397
  -1,599
  -1,816
  -2,047
  -2,293
  -2,553
  -2,827
  -3,114
  -3,415
  -3,729
  -4,056
  -4,397
  -4,752
  -5,121
  -5,504
Change in working capital, $m
  -6
  -8
  -11
  -15
  -20
  -26
  -33
  -40
  -48
  -57
  -66
  -76
  -85
  -95
  -105
  -115
  -124
  -133
  -142
  -151
  -160
  -168
  -177
  -185
  -193
  -201
  -210
  -218
  -227
  -236
Cash from operations, $m
  -79
  -91
  -107
  -129
  -158
  -195
  -243
  -301
  -372
  -457
  -556
  -670
  -799
  -945
  -1,106
  -1,283
  -1,475
  -1,683
  -1,905
  -2,142
  -2,393
  -2,659
  -2,938
  -3,230
  -3,536
  -3,855
  -4,188
  -4,534
  -4,894
  -5,269
Maintenance CAPEX, $m
  0
  -1
  -1
  -2
  -3
  -4
  -6
  -7
  -10
  -13
  -16
  -20
  -24
  -29
  -35
  -41
  -47
  -54
  -62
  -70
  -79
  -88
  -98
  -108
  -119
  -130
  -142
  -154
  -167
  -180
New CAPEX, $m
  -2
  -2
  -3
  -4
  -6
  -8
  -9
  -12
  -14
  -17
  -19
  -22
  -25
  -28
  -30
  -33
  -36
  -39
  -41
  -44
  -46
  -49
  -51
  -53
  -56
  -58
  -61
  -63
  -66
  -68
Cash from investing activities, $m
  -2
  -3
  -4
  -6
  -9
  -12
  -15
  -19
  -24
  -30
  -35
  -42
  -49
  -57
  -65
  -74
  -83
  -93
  -103
  -114
  -125
  -137
  -149
  -161
  -175
  -188
  -203
  -217
  -233
  -248
Free cash flow, $m
  -82
  -94
  -112
  -135
  -167
  -207
  -258
  -320
  -396
  -486
  -591
  -711
  -848
  -1,001
  -1,171
  -1,356
  -1,558
  -1,775
  -2,008
  -2,256
  -2,519
  -2,796
  -3,087
  -3,392
  -3,711
  -4,043
  -4,390
  -4,751
  -5,126
  -5,516
Issuance/(repayment) of debt, $m
  11
  13
  19
  25
  33
  43
  54
  66
  80
  94
  109
  125
  141
  157
  173
  188
  204
  219
  234
  249
  263
  277
  290
  304
  317
  331
  345
  359
  373
  388
Issuance/(repurchase) of shares, $m
  153
  183
  236
  305
  390
  495
  619
  764
  930
  1,116
  1,322
  1,548
  1,792
  2,052
  2,329
  2,621
  2,927
  3,247
  3,580
  3,925
  4,283
  4,653
  5,036
  5,432
  5,842
  6,266
  6,705
  7,159
  7,630
  8,119
Cash from financing (excl. dividends), $m  
  164
  196
  255
  330
  423
  538
  673
  830
  1,010
  1,210
  1,431
  1,673
  1,933
  2,209
  2,502
  2,809
  3,131
  3,466
  3,814
  4,174
  4,546
  4,930
  5,326
  5,736
  6,159
  6,597
  7,050
  7,518
  8,003
  8,507
Total cash flow (excl. dividends), $m
  83
  102
  143
  195
  257
  331
  416
  510
  614
  724
  841
  961
  1,084
  1,208
  1,331
  1,453
  1,573
  1,691
  1,805
  1,917
  2,027
  2,134
  2,240
  2,344
  2,449
  2,553
  2,659
  2,767
  2,877
  2,990
Retained Cash Flow (-), $m
  -153
  -183
  -236
  -305
  -390
  -495
  -619
  -764
  -930
  -1,116
  -1,322
  -1,548
  -1,792
  -2,052
  -2,329
  -2,621
  -2,927
  -3,247
  -3,580
  -3,925
  -4,283
  -4,653
  -5,036
  -5,432
  -5,842
  -6,266
  -6,705
  -7,159
  -7,630
  -8,119
Prev. year cash balance distribution, $m
  138
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  67
  -81
  -93
  -110
  -133
  -164
  -204
  -254
  -316
  -392
  -482
  -587
  -708
  -845
  -998
  -1,168
  -1,354
  -1,556
  -1,774
  -2,008
  -2,256
  -2,519
  -2,796
  -3,088
  -3,393
  -3,712
  -4,045
  -4,392
  -4,753
  -5,129
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  65
  -74
  -81
  -91
  -103
  -119
  -138
  -159
  -182
  -205
  -229
  -250
  -269
  -284
  -293
  -297
  -295
  -287
  -273
  -255
  -233
  -209
  -183
  -157
  -132
  -108
  -87
  -68
  -52
  -39
Current shareholders' claim on cash, %
  27.6
  10.1
  4.1
  1.8
  0.9
  0.4
  0.2
  0.1
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Chimerix, Inc. is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses. It is also advancing the development of CMX521 for the treatment and prevention of norovirus. In addition, the Company has an active discovery program focusing on viral targets for which limited or no therapies are available. Brincidofovir is an investigational oral nucleotide analog that has shown spectrum antiviral activity against all five families of double-stranded deoxyribonucleic acid (dsDNA) viruses that affect humans. Oral and IV formulations of brincidofovir are in development, both of which deliver the active antiviral directly to the site of viral replication.

FINANCIAL RATIOS  of  Chimerix (CMRX)

Valuation Ratios
P/E Ratio -1.9
Price to Sales 24.6
Price to Book 0.5
Price to Tangible Book
Price to Cash Flow -2.3
Price to Free Cash Flow -2.3
Growth Rates
Sales Growth Rate -45.5%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -50%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -23.6%
Ret/ On Assets - 3 Yr. Avg. -29.5%
Return On Total Capital -24.9%
Ret/ On T. Cap. - 3 Yr. Avg. -31.1%
Return On Equity -24.9%
Return On Equity - 3 Yr. Avg. -31.6%
Asset Turnover 0
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -1250%
EBITDA Margin - 3 Yr. Avg. -1251.5%
Operating Margin -1300%
Oper. Margin - 3 Yr. Avg. -1282.6%
Pre-Tax Margin -1266.7%
Pre-Tax Margin - 3 Yr. Avg. -1268.4%
Net Profit Margin -1266.7%
Net Profit Margin - 3 Yr. Avg. -1268.4%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

CMRX stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the CMRX stock intrinsic value calculation we used $4.494 million for the last fiscal year's total revenue generated by Chimerix. The default revenue input number comes from 0001 income statement of Chimerix. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our CMRX stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for CMRX is calculated based on our internal credit rating of Chimerix, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Chimerix.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of CMRX stock the variable cost ratio is equal to 425%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $61 million in the base year in the intrinsic value calculation for CMRX stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Chimerix.

Corporate tax rate of 27% is the nominal tax rate for Chimerix. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the CMRX stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for CMRX are equal to 59.2%.

Life of production assets of 2.2 years is the average useful life of capital assets used in Chimerix operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for CMRX is equal to -204.6%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $221.81 million for Chimerix - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 47.753 million for Chimerix is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Chimerix at the current share price and the inputted number of shares is $0.2 billion.

RELATED COMPANIES Price Int.Val. Rating
VICL Vical 1.27 0.72  sell
GILD Gilead Science 70.92 155.76  str.buy
MRK Merck&Co 74.61 33.05  str.sell
FATE Fate Therapeut 13.08 0.37  str.sell

COMPANY NEWS

▶ Chimerix: 3Q Earnings Snapshot   [Nov-08-18 07:44AM  Associated Press]
▶ The most valuable public companies in the Triangle (Slideshow)   [Nov-05-18 02:29PM  American City Business Journals]
▶ Chimerix to Host Annual Investor Update on October 17, 2018   [Oct-11-18 04:01PM  GlobeNewswire]
▶ Inside The List: Highest-Paid Public Company CEOs   [Sep-04-18 02:38PM  American City Business Journals]
▶ Chimerix to Participate in September Investor Conferences   [Aug-29-18 07:00AM  GlobeNewswire]
▶ Chimerix: 2Q Earnings Snapshot   [08:43AM  Associated Press]
▶ Chimerix, Inc. to Host Earnings Call   [06:30AM  ACCESSWIRE]
▶ What new FDA designation means for Durham's Chimerix   [Jun-08-18 02:17PM  American City Business Journals]
▶ Benzinga Pro's 5 Stocks To Watch Today   [Jun-07-18 08:41AM  Benzinga]
▶ Chimerix: 1Q Earnings Snapshot   [07:29AM  Associated Press]
▶ Chimerix, Inc. to Host Earnings Call   [06:30AM  ACCESSWIRE]
▶ Look what Triangle woman just became chairwoman of a $250M company   [Mar-30-18 03:11PM  American City Business Journals]
▶ Durham pharma pushing to fight a common cold virus that's deadly to some patients   [Mar-23-18 08:48AM  American City Business Journals]
▶ Chimerix reports 4Q loss   [08:13AM  Associated Press]
▶ Chimerix, Inc. to Host Earnings Call   [06:55AM  ACCESSWIRE]
▶ Could These 2 Biotech Stocks Really Double Your Money?   [Feb-15-18 07:39AM  Motley Fool]
▶ ETFs with exposure to Chimerix, Inc. : December 28, 2017   [Dec-28-17 11:57AM  Capital Cube]
▶ Should You Buy Chimerix Inc (CMRX)?   [Nov-08-17 09:39AM  Simply Wall St.]
▶ Chimerix reports 3Q loss   [07:23AM  Associated Press]
▶ Chimerix, Inc. to Host Earnings Call   [06:40AM  ACCESSWIRE]
▶ ETFs with exposure to Chimerix, Inc. : October 11, 2017   [Oct-11-17 11:20AM  Capital Cube]
▶ ETFs with exposure to Chimerix, Inc. : August 31, 2017   [Aug-31-17 05:48PM  Capital Cube]
▶ Chimerix reports 2Q loss   [Aug-07-17 11:55PM  Associated Press]
▶ ETFs with exposure to Chimerix, Inc. : June 27, 2017   [Jun-27-17 03:04PM  Capital Cube]
▶ ETFs with exposure to Chimerix, Inc. : June 5, 2017   [Jun-05-17 02:09PM  Capital Cube]
▶ Chimerix outlines plans for DNA virus drug   [May-10-17 08:15AM  American City Business Journals]
▶ Chimerix reports 1Q loss   [May-09-17 08:45AM  Associated Press]
▶ ETFs with exposure to Chimerix, Inc. : April 24, 2017   [Apr-24-17 02:21PM  Capital Cube]
▶ Chimerix to Host Annual Investor Update on April 27, 2017   [Apr-20-17 08:00AM  GlobeNewswire]
▶ ETFs with exposure to Chimerix, Inc. : April 7, 2017   [Apr-07-17 04:11PM  Capital Cube]
▶ ETFs with exposure to Chimerix, Inc. : March 27, 2017   [Mar-27-17 03:53PM  Capital Cube]
▶ Chimerix reports 4Q loss   [07:29AM  Associated Press]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.